Atlas Global Announces Changes to Canadian Operations
CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, June 02, 2023 (GLOBE NEWSWIRE) — Atlas Global Brands Inc….
CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, June 02, 2023 (GLOBE NEWSWIRE) — Atlas Global Brands Inc….
Changes in line with Vision 2025 strategy David Hayes named Chief Financial Officer IRVINE, Calif.–(BUSINESS…
Changes in line with Vision 2025 strategy David Hayes named Chief Financial Officer IRVINE, Calif.–(BUSINESS…
PHILADELPHIA–(BUSINESS WIRE)–Today, Delaware Investments National Municipal Income Fund (the “Fund”), a New York Stock Exchange…
PHILADELPHIA–(BUSINESS WIRE)–Today, Delaware Investments National Municipal Income Fund (the “Fund”), a New York Stock Exchange…
First Quarter 2023 Highlights 1Q 2023 Invoiced Sales Amounted to €86.1 Million, a Decrease of…
First Quarter 2023 Highlights 1Q 2023 Invoiced Sales Amounted to €86.1 Million, a Decrease of…
ITASCA, Ill.–(BUSINESS WIRE)–FG Financial Group, Inc. (Nasdaq: FGF) (the “Company”), a reinsurance and asset management…
ITASCA, Ill.–(BUSINESS WIRE)–FG Financial Group, Inc. (Nasdaq: FGF) (the “Company”), a reinsurance and asset management…
VANCOUVER, British Columbia, June 02, 2023 (GLOBE NEWSWIRE) — Agra Ventures Ltd. (“AGRA” or the…
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in…
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company…
PRINCETON, N.J., June 02, 2023 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader…
SOUTH SAN FRANCISCO and SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc….
NEW YORK–(BUSINESS WIRE)–On May 25, 2023, Clarion Capital Partners, LLC (“Clarion”) completed an investment in…
NEW YORK–(BUSINESS WIRE)–On May 25, 2023, Clarion Capital Partners, LLC (“Clarion”) completed an investment in…
YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on…
Industry luminaries, including Wait But Why’s Tim Urban, to explore the best practices in generative…
PASADENA, CA, June 02, 2023 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the…
Phase 1 trial to resume with weekly dosing, a focus on patients with ovarian cancer…